United States:
FDA Publishes Notice Of Patent Infringement Complaint Filed Against A Biosimilar Applicant
15 September 2015
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In the August 24, 2015, Federal
Register, FDA announced that an applicant for a
proposed biosimilar product had notified FDA that a patent
infringement action has been filed in connection with the
applicant's BLA. FDA received notice of the following
complaint: Janssen Biotech, Inc., et. al. v. Celltrion
Healthcare Co., Ltd., et al., 15–cv–10698 (D.
Mass., filed March 6, 2015).
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Manatt Health: Health AI Policy Tracker
Manatt, Phelps & Phillips LLP
The purpose of this quarterly tracker is to identify key federal and state health AI policy activity. Below reflects federal legislative and regulatory activity to date related to AI...